Biogen (BIIB) AI Analysis

BIIB$253.40+2.92 +1.17%
Drug Manufacturers - GeneralLarge Cap
Compare
Market cap$37.46BEnterprise value$44.11BRevenue (TTM)$10.30BMarket positionTop 25%

Score

34
Bearish
Value
40
Quality
36
Growth
26

AI Score 55. Biogen Inc. has a high price-to-earnings ratio of approximately 107.5, indicating potential overvaluation, while its recent net income figures show volatility, including a loss of $68.1 million in Q3 2023

Biogen (BIIB) AI Analysis

BIIB price $253.40 +2.92 +1.17%

Ticker
BIIB
Price
$253.40
Change
+2.92 +1.17%
Market cap
$37.46B
P/E
107.64
Forward P/E
17.21
Dividend yield
0.00%
Beta
0.17
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
34
Value
40
Quality
36
Growth
26

Stocklytics score rationale: value 40, quality 36, growth 26.

AI Score 55. Biogen Inc. has a high price-to-earnings ratio of approximately 107.5, indicating potential overvaluation, while its recent net income figures show volatility, including a loss of $68.1 million in Q3 2023

Insights · Forecast · Financials · Learn

Stocklytics home · Screener